Metvan, bis(4,7-dimethyl-1,10-phenanthroline)sulfato-oxidovanadium(IV): DFT and Spectroscopic Study. Antitumor Action on Human Bone and Colorectal Cancer Cell Lines

BARAN E.J; LEON I.E; RUIZ M.C; FRANCA C; PARAJON- COSTA B.

Simposio; V11 International Simposium of Vanadium; 2018

The complex bis(4,7-dimethyl-1,10-phenantroline)sulfatooxido-vanadium(IV), commonly known as Metvan, was prepared using a known synthetic procedure [1]. Its optimized molecular structure was obtained by DFT calculations, as it was impossible to grow single crystals adequate for a crystallographic study. The complex was also characterized by a detailed analysis of its infrared spectrum, supported by the theoretical calculations, and also by some data derived from its Raman spectrum. In addition, cytotoxicity studies were performed using human osteosarcoma (MG-63) and human colorectal adenocarcinoma (HT-29) cell lines. The results showed that Metvan impaired cell viability of both cancer cell lines in a low concentration range (0.25-5.00 M). The IC50 values for HT-29 are 0.39 ± 0.07 M (fresh Metvan) and 0.33 ± 0.09 M (aged Metvan) while for MG-63 the values are 0.75 ± 0.02 M (fresh Metvan) and 0.83 ± 0.18 M (aged Metvan). These results considered together show that the anticancer activity of Metvan is much stronger in colorectal tumor cells than in bone cancer cells. Finally, the biological results between fresh and aged Metvan are similar, suggesting that the speciation of the complex does not affect its anticancer activity towards colorectal and bone cancer cells.